| Wissenschaftl. Titel | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib |
| Erkrankung |
Blut:
Myeloische Neoplasien/Dysplasien:
Myeloproliferative Neoplasien (MPN)
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Studiendokumente zum Download (roXtra) |
erstellt 15.09.2020 Sina Hehn
geändert 20.04.2022 Sina Hehn